Subscribe
shutterstock_660852628_panchenko_vladimir
Panchenko Vladimir / Shutterstock.com
10 March 2020AmericasSarah Morgan

Par avoids pay-for-delay suit after court accepts payment was ‘fair’

A Virginia judge has approved Par Pharmaceutical’s settlement with a group of direct purchasers, allowing the pharmaceutical company to escape a pay-for-delay lawsuit.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
MSD and Glenmark appeal pay-for-delay Zetia dispute
7 January 2021   Pharmaceutical companies MSD and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia should be reversed because the circumstances of the class members do not justify an award of class status.
Generics
Glenmark becomes fifth generic to be charged with US antitrust violations
2 July 2020   Glenmark Pharmaceuticals has been charged with conspiring to fix prices for generic drugs, according to a statement released by the US Department of Justice.
Big Pharma
AG advises CJEU to uphold €94 million pay-for-delay fine
5 June 2020   The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
MSD and Glenmark appeal pay-for-delay Zetia dispute
7 January 2021   Pharmaceutical companies MSD and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia should be reversed because the circumstances of the class members do not justify an award of class status.
Generics
Glenmark becomes fifth generic to be charged with US antitrust violations
2 July 2020   Glenmark Pharmaceuticals has been charged with conspiring to fix prices for generic drugs, according to a statement released by the US Department of Justice.
Big Pharma
AG advises CJEU to uphold €94 million pay-for-delay fine
5 June 2020   The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.

More on this story

Americas
MSD and Glenmark appeal pay-for-delay Zetia dispute
7 January 2021   Pharmaceutical companies MSD and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia should be reversed because the circumstances of the class members do not justify an award of class status.
Generics
Glenmark becomes fifth generic to be charged with US antitrust violations
2 July 2020   Glenmark Pharmaceuticals has been charged with conspiring to fix prices for generic drugs, according to a statement released by the US Department of Justice.
Big Pharma
AG advises CJEU to uphold €94 million pay-for-delay fine
5 June 2020   The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB